Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]
Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by Leerink Partners.